AngioDynamics Wins Approval To Expand Its Equity Incentive Share Pool

The amendment to the existing 2020 plan passed by 26,990,852 votes to 3,784,918 at Tuesday's annual meeting.

Share
AngioDynamics Wins Approval To Expand Its Equity Incentive Share Pool

AngioDynamics, which makes medical devices for cardiovascular disease and cancer, won shareholder approval Tuesday to expand the shares available under its equity incentive plan. The amendment passed by 26,990,852 votes to 3,784,918, according to the company's SEC report filed Wednesday.

A Larger Pool Under The 2020 Plan

The approval expands the pool of stock AngioDynamics can issue through its existing 2020 equity incentive plan. The company outlined the proposal in its October 8, 2026 annual proxy filing.

The amendment received 31,947 abstentions. Another 5,872,140 shares were broker non-votes—shares held through brokers that were not voted on the proposal.

Devices For Arteries, Clots And Tumors

AngioDynamics operates through its Med Tech and Med Device segments. Med Tech includes Auryon, a system used to treat peripheral artery disease; AngioVac and AlphaVac clot-removal devices; and NanoKnife, its tumor ablation system.

Med Device includes angiographic and drainage catheters, guidewires and implantable ports used to deliver cancer drugs. The segment also offers a laser system for varicose veins and microwave ablation products.

The company sells to specialists including interventional radiologists, cardiologists, vascular surgeons, urologists and surgical oncologists, as well as critical care nurses. It primarily uses its own sales force in the United States and combines direct sales with distributors abroad.

AngioDynamics makes certain products at leased facilities in Queensbury and Glens Falls, New York. Third-party manufacturers supply other products.

Director Elections And Executive Pay

Shareholders elected Eileen O. Auen and Jan Stern Reed to board terms ending at the 2029 annual shareholder meeting. Auen received 28,252,245 votes in favor and 2,555,472 withheld; Reed received 27,956,254 in favor and 2,851,463 withheld. Each election had 5,872,140 broker non-votes.

The advisory vote on executive pay passed by 29,073,414 votes to 1,691,653. Shareholders recorded 42,650 abstentions, alongside 5,872,140 broker non-votes.

Shareholders ratified Deloitte & Touche LLP as independent auditor for the fiscal year ending May 31, 2027. That proposal received 36,287,806 votes in favor, 381,289 against and 10,762 abstentions.

Sources

More on AngioDynamics

All AngioDynamics (ANGO) coverage →